NCT04594187 2026-02-17
MelPORT
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
12 trialsNCT01416831 2025-03-17
SBRT/IL-2
Providence Health & Services
Phase 2 Active not recruiting
NCT01973322 2025-01-09
ABSIDE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT03758729 2021-02-16
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Samsung Medical Center
Phase 2 Withdrawn
NCT02562625 2020-04-09
PERM
Royal Marsden NHS Foundation Trust
Phase 2 Terminated
NCT01449279 2020-03-02
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
Stanford University
Phase 2 Completed
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01689974 2018-02-23
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
NYU Langone Health
Phase 2 Terminated
NCT00707161 2017-03-31
Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
University of Utah
Phase 2 Terminated
NCT00060333 2017-03-17
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00096382 2015-10-28
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00006233 2011-11-30
Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Phase 2 Completed